ProKidney Corp., a company specializing in cell therapeutics for chronic kidney disease, has announced the positive topline results from its Phase 2 REGEN-007 study. The study demonstrated a 78% improvement in the eGFR slope in Group 1 after treatment with rilparencel. Full results from the REGEN-007 study are set to be submitted as a late-breaking clinical trial at the American Society of Nephrology 2025 Kidney Week. Additionally, the FDA has confirmed the use of the eGFR slope as a surrogate endpoint for accelerated approval of rilparencel in patients with type 2 diabetes and advanced chronic kidney disease. The ongoing Phase 3 PROACT 1 study will serve as both the accelerated approval and confirmatory study, with topline data expected in the second quarter of 2027. ProKidney continues to enroll patients for this study and aims to bring a novel treatment option to address the unmet clinical needs in this patient population.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。